More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk

Statistics in Medicine

Volumn 24, Issue 1, 2005, Pages 11-21

  McMahon, Robert P ^a   Arndt, Stephan ^b   Conley, Robert R ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Clinical trials; Longitudinal data; Non normal responses; Rank correlation; Schizophrenia; Subgroup effects

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; NEGATIVE SYNDROME; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIMULATION;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CHLORPROMAZINE; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; HUMANS; PSYCHIATRY; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA;

EID: 11344286277     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1837     Document Type: Article

References (12)

1. Arndt S, Davis CS, Miller DD, Andreasen NC. Effect of antipsychotic withdrawal on extrapyramidal symptoms: statistical methods for analysing single-sample repeated-measures data. Neuropsychopharmacology 1993; 8: 67-75.
2. Salsburg D. Alternative hypotheses for the effects of drugs in small-scale clinical studies. Biometrics 1986; 42:671-674.
3. Conover WJ, Salsburg DS. Locally most powerful tests for detecting treatment effects when only a subset of participants can be expected to 'respond' to treatment. Biometrics 1988; 44 189-196.
4. Razzaghi M, Nanthakumar A. On using Lehman alternatives with nonresponders. Mathematical Biosciences 1992; 109:69-83.
5. Arndt S, Turvey C, Coryell WH, Dawson JH, Leon AC, Akiskal HS. Charting participants' course: a comparison of statistics used to summarize participant course in longitudinal and repeated measures studies. Journal of Psychiatric Research 2000; 34:105-113.
6. Kraemer HC, Thiemann S. A strategy to use soft data effectively in randomized controlled clinical trials. Journal of Consulting and Clinical Psychology 1989; 57:154.
7. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry 1998; 155:914-920.
8. Overall JE, Gorman DR. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacology Bulletin 1988; 24:97-99.
9. Simpson GW, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavia (Suppl.) 1970; 212 11-19.
10. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Statistics in Medicine 1997; 16:2349-2380.
11. Efron B, Tibshirani R. An Introduction to the Bootstrap Chapman & Hall: New York, 1993.
12. Lo Y, Matthyse S, Rubin DB, Holzman PS. Permutation tests for detecting and estimating mixtures in task performance within groups. Statistics in Medicine 2002; 21:1937-1953.